Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation

J Immunol. 1999 Aug 15;163(4):2151-9.

Abstract

Angiogenesis is a critical process for growth of new capillary blood vessels from preexisting capillaries and postcapillary venules, both in physiological and pathological conditions. Endothelial cell proliferation is a major component of angiogenesis and it is regulated by several growth factors. It has been previously shown that the human hemopoietic growth factor IL-3 (hIL-3), predominantly produced by activated T lymphocytes, stimulates both endothelial cell proliferation and functional activation. In the present study, we report that hIL-3 is able to induce directional migration and tube formation of HUVEC. The in vivo neoangiogenetic effect of hIL-3 was also demonstrated in a murine model in which Matrigel was used for the delivery of the cytokine, suggesting a role of hIL-3 in sustaining neoangiogenesis. Challenge of HUVEC with hIL-3 lead to the synthesis of platelet-activating factor (PAF), which was found to act as secondary mediator for hIL-3-mediated endothelial cell motility but not for endothelial cell proliferation. Consistent with the role of STAT5 proteins in regulating IL-3-mediated mitogenic signals, we herein report that, in hIL-3-stimulated HUVEC, the recruitment of STAT5A and STAT5B, by the beta common (betac) subunit of the IL-3R, was not affected by PAF receptor blockade.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoproteins D
  • Apolipoproteins*
  • Azepines / pharmacology
  • Carrier Proteins / metabolism
  • Cell Division / drug effects
  • Cell Line
  • Cell Movement / drug effects
  • Cell Movement / physiology*
  • DNA-Binding Proteins / antagonists & inhibitors
  • DNA-Binding Proteins / metabolism
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiology*
  • Female
  • Glycoproteins*
  • Humans
  • Injections, Subcutaneous
  • Interleukin-3 / administration & dosage*
  • Interleukin-3 / metabolism
  • Interleukin-3 / physiology*
  • Macromolecular Substances
  • Membrane Transport Proteins*
  • Mice
  • Mice, Inbred C57BL
  • Milk Proteins*
  • Neovascularization, Physiologic / drug effects
  • Neovascularization, Physiologic / physiology*
  • Platelet Activating Factor / antagonists & inhibitors
  • Platelet Activating Factor / biosynthesis
  • Platelet Membrane Glycoproteins / antagonists & inhibitors
  • Protein Binding
  • Receptors, Cell Surface*
  • Receptors, G-Protein-Coupled*
  • Receptors, Interleukin-3 / metabolism
  • STAT5 Transcription Factor
  • Trans-Activators / antagonists & inhibitors
  • Trans-Activators / metabolism
  • Triazoles / pharmacology
  • Tumor Suppressor Proteins

Substances

  • APOD protein, human
  • Apolipoproteins
  • Apolipoproteins D
  • Azepines
  • Carrier Proteins
  • DNA-Binding Proteins
  • Glycoproteins
  • Interleukin-3
  • Macromolecular Substances
  • Membrane Transport Proteins
  • Milk Proteins
  • Platelet Activating Factor
  • Platelet Membrane Glycoproteins
  • Receptors, Cell Surface
  • Receptors, G-Protein-Coupled
  • Receptors, Interleukin-3
  • STAT5 Transcription Factor
  • STAT5A protein, human
  • STAT5B protein, human
  • Stat5a protein, mouse
  • Stat5b protein, mouse
  • Trans-Activators
  • Triazoles
  • Tumor Suppressor Proteins
  • platelet activating factor receptor
  • bepafant